A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2016

At a glance

  • Drugs Eluxadoline (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Furiex Pharmaceuticals
  • Most Recent Events

    • 24 May 2016 Pooled safety analysis (n=3202) of 3 studies (IBS-2001, IBS-3001 and IBS-3002) presented at the Digestive Disease Week 2016
    • 22 May 2012 Patient-reported efficacy outcomes presented at Digestive Disease Week 2012.
    • 31 Oct 2011 Results were reported at the American College of Gastroenterology 2011 Annual Scientific Meeting, according to a Furiex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top